Nanotechnology‐based approaches for treating lysosomal storage disorders, a focus on Fabry disease
Ibane Abasolo(Unknown), Simó Schwartz(CIBBIM-Nanomedicine), José Luís Corchero(Universitat Autònoma de Barcelona), Marc Moltó‐Abad(Universitat Autònoma de Barcelona), Vanessa Díaz‐Riascos(Universitat Autònoma de Barcelona), Guillem Pintos‐Morell(Hospital Universitari Germans Trias i Pujol), Joaquin Seras‐Franzoso(Vall d'Hebron Institut de Recerca)
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
December 13, 2020
Cited by 26
Related Papers
Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism–dystonia
|Nature Communications|2016|326
The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype
|Journal of Inherited Metabolic Disease|2015|236
Bacterial Inclusion Bodies: Discovering Their Better Half
|Trends in Biochemical Sciences|2017|181
Fabry disease and the skin: data from FOS, the Fabry outcome survey
|British Journal of Dermatology|2007|178
Bacterial inclusion bodies: making gold from waste
|Trends in biotechnology|2011|173